- Home
- SCHW vs GILD Comparison
SCHW vs GILD Comparison
Compare SCHW & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SCHW | GILD |
|---|---|---|
| Founded | 1971 | 1987 |
| Country | United States | United States |
| Employees | 33500 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.5B | 155.3B |
| IPO Year | N/A | 2003 |
Fundamental Metrics
Financial Performance| Metric | SCHW | GILD |
|---|---|---|
| Price | $101.75 | $136.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 18 |
| Target Price | $112.56 | ★ $148.39 |
| AVG Volume (30 Days) | ★ 11.1M | 7.6M |
| Earning Date | 04-16-2026 | 05-07-2026 |
| Dividend Yield | 1.40% | ★ 2.55% |
| EPS Growth | N/A | ★ 1684.21 |
| EPS | N/A | ★ 1.61 |
| Revenue | N/A | ★ $24,689,000,000.00 |
| Revenue This Year | $13.87 | $4.68 |
| Revenue Next Year | $9.39 | $6.04 |
| P/E Ratio | ★ $20.51 | $84.81 |
| Revenue Growth | N/A | ★ 9.98 |
| 52 Week Low | $83.96 | $107.75 |
| 52 Week High | $107.50 | $157.29 |
Technical Indicators
Market Signals| Indicator | SCHW | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 72.91 | 62.82 |
| Support Level | $99.51 | $133.89 |
| Resistance Level | $106.02 | $137.35 |
| Average True Range (ATR) | 2.41 | 3.52 |
| MACD | 1.22 | 1.42 |
| Stochastic Oscillator | 93.07 | 85.13 |
Price Performance
Historical ComparisonAbout SCHW Charles Schwab Corporation (The)
Charles Schwab is one of the largest retail-oriented financial-services companies in the US, with $11.9 trillion in client assets across its brokerage, banking, asset management, custody, financial advisory, and wealth management businesses at the end of 2025. While best known for its retail brokerage offering, Schwab generates the lion's share of its revenue and profits through its Charles Schwab Bank and asset management segments. The firm is a dominant player in Registered Investment Advisor(RIA) custody, with over 40% market share, and has recently pushed into wealth management with robo-advisory, direct indexing, and other managed-investment solutions.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).